CLXT - Calyxt, Inc.
| Previous close | 5.97 |
| Open | 6.16 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 1000 |
| Day's range | 6.01 - 7.77 |
| 52-week range | 6.01 - 30.50 |
| Volume | |
| Avg. volume | 11,542 |
| Market cap | 31.334M |
| Beta (5Y monthly) | 2.04 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.83 |
| Earnings date | 02 Aug 2023 - 07 Aug 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 7.25 |
PR NewswireCalyxt Announces Stockholder Approval of Merger With Cibus
Calyxt, Inc. (Nasdaq: CLXT) ("Calyxt" or the "Company") today announced the results of the special meeting of its stockholders held on May 18, 2023. At the special meeting, Calyxt's stockholders voted in favor of all proposals, including the proposal to approve the issuance of shares of Class A common stock and Class B common stock to the equity holders of Cibus Global, LLC ("Cibus") as part of the previously announced proposed merger with Cibus.
- PR Newswire
Calyxt Reports First Quarter 2023 Financial Results and Provides Corporate Update
Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, today announced operating and financial results for its first quarter ended March 31, 2023.
- PR Newswire
Calyxt Completes One-for-Ten Reverse Stock Split
Calyxt, Inc. (Nasdaq: CLXT) ("Calyxt" or the "Company") today announced that it has completed the previously announced reverse stock split of Calyxt's common stock, par value $0.0001 per share ("Common Stock"), at a ratio of 1-for-10. The reverse stock split was previously approved by the Company's stockholders at the annual meeting of shareholders on June 1, 2022.
- PR Newswire
Calyxt, Inc. Announces Effectiveness of Registration Statement on Form S-4 in Connection with Merger with Cibus Global LLC
Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, and Cibus, a leader in precision gene editing in agriculture, today announced that the registration statement on Form S-4, initially filed with the U.S. Securities and Exchange Commission ("SEC") by Calyxt on February 14, 2023, and amended on April 14, 2023 (as amended, the "Registration Statement"), has been declared effective by the SEC.
PR NewswireCalyxt Announces Effective Date of Reverse Stock Split
Calyxt, Inc. (Nasdaq: CLXT) ("Calyxt" or the "Company") today announced that it will proceed with the 1-for-10 reverse stock split previously approved by the Company's shareholders at the annual meeting of shareholders on June 1, 2022. Calyxt plans to file an amendment to its certificate of incorporation to effectuate the reverse stock split after the close of trading on April 24, 2023, and Calyxt's common stock, par value $0.0001 per share, will begin trading on an adjusted basis giving effect
GlobeNewswireCalyxt, Inc. Reports its Fourth Quarter 2022 Financial Results and Provides Corporate Update
NEW YORK, March 06, 2023 (GLOBE NEWSWIRE) -- Cellectis S.A. (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company for which Cellectis owns 49.1% (as of December 31, 2022) of its issued and outstanding common stock, today announced operating and financial results for its fourth quarter ended D
- PR Newswire
Calyxt Reports Fourth Quarter 2022 Financial Results and Provides Corporate Update
Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, today announced operating and financial results for its fourth quarter ended December 31, 2022.
- PR Newswire
Calyxt, Inc. Announces its Filing of Registration Statement on Form S-4 in Connection with Merger with Cibus Global LLC
Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, and Cibus, a leader in precision gene editing in agriculture, today announced that Calyxt has filed a registration statement on Form S-4 (the "Registration Statement") with the U.S. Securities and Exchange Commission ("SEC") on February 14, 2023. The combined company is expected to be renamed Cibus, Inc. and remain listed on the Nasdaq Capital Market under the proposed ticker symbol CBUS.
- GlobeNewswire
Calyxt and Cibus Announce the Signing of a Definitive Merger Agreement
NEW YORK, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its gene editing platform to deliver life-saving cell and gene therapies, announced today that Cibus Global LLC, a Delaware limited liability company (“Cibus”), and Calyxt, Inc. (NASDAQ: CLXT) (“Calyxt”), announced that Calyxt and Calypso Merger Subsidiary, LLC, a Delaware limited liability company and wholly-owned subsidiary of Calyxt, entered into an Agree
- PR Newswire
Calyxt and Cibus Announce Definitive Merger Agreement to Create Industry-Leading Precision Gene Editing and Trait Licensing Company
Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, and Cibus, a leader in precision gene editing in agriculture, today announced that both companies have entered into a definitive merger agreement under which Calyxt and Cibus will merge in an all-stock transaction. The merger will create a new industry-leading company that combines the two pioneers in agriculture-based gene editing and establishes one of the world's most sophisticated facilities for trait development and next-
- PR Newswire
Calyxt Achieves Phase 1 Milestone in Collaboration Agreement to Develop Alternative to Palm Oil
Calyxt, Inc. (NASDAQ: CLXT), a plant-based synthetic biology company announced today that it has successfully completed the first phase in its research collaboration agreement with a leading global food ingredient manufacturer based in Asia to develop an improved soybean capable of producing an oil as a commercial alternative to palm oil.
- PR Newswire
Calyxt Granted 180-Day Extension by Nasdaq to Regain Compliance with Bid Price Rule
Calyxt, Inc (Nasdaq: CLXT) a plant-based synthetic biology focused on engineering sustainable ingredients for customers in the cosmeceutical, nutraceutical and pharmaceutical industries, today announced that the Company received written notification from the Listing Qualifications Department of The Nasdaq Stock Market, LLC ("Nasdaq"), granting the Company's request for a 180-day extension to regain compliance with Nasdaq's minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the "
Simply Wall St.Calyxt Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag
Calyxt ( NASDAQ:CLXT ) Third Quarter 2022 Results Key Financial Results Revenue: US$42.0k (down 100% from 3Q 2021). Net...
ZacksCalyxt (CLXT) Reports Q3 Loss, Misses Revenue Estimates
Calyxt (CLXT) delivered earnings and revenue surprises of 13.33% and 86%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- PR Newswire
Calyxt Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, today announced operating and financial results for its third quarter ended September 30, 2022.
- PR Newswire
Calyxt Joins Bioindustrial Manufacturing and Design Ecosystem (BioMADE), a Department of Defense Initiative, to Advance Sustainable Plant-Based Biomanufacturing
Calyxt, Inc. (NASDAQ: CLXT), a plant-based synthetic biology company, announced today that it has become a member of Bioindustrial Manufacturing and Design Ecosystem (BioMADE), a Department of Defense initiated Manufacturing Innovation Institute dedicated to advancing bioindustrial manufacturing across the nation.
- PR Newswire
Calyxt to Host Third Quarter 2022 Financial Results Conference Call and Webcast on Thursday, November 3, 2022, at 4:30 p.m. Eastern Time
Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, will host a conference call and webcast on Thursday, November 3, 2022, at 4:30 p.m. ET to discuss results for the third quarter ended September 30, 2022. A press release detailing these results will be issued prior to the call.
- PR Newswire
Calyxt Successfully Produces Plant-Based Squalene, an Important Ingredient in Personal Care Products and Critical Vaccine Adjuvants
Calyxt, Inc. (NASDAQ: CLXT), a plant-based synthetic biology company, announced today that using a Calyxt-engineered Plant Cell Matrix™ biomass, it has successfully produced squalene, an important ingredient in many personal care products and vaccine adjuvants, including several strands of flu and COVID-19 vaccines.
- PR Newswire
Calyxt Announces Agreement with Evologic Technologies to Scale Production of its Plant-based Ingredients
Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, today announced that it has signed an agreement with its first manufacturing partner, Evologic Technologies GmbH, to further develop and scale Calyxt's proprietary Plant Cell Matrix™ (PCM™) technology platform.
- PR Newswire
Calyxt, Inc. Exploring Strategic Alternatives
Calyxt, Inc. (NASDAQ: CLXT) ("Calyxt"), a plant-based synthetic biology company, today announced that its Board of Directors is evaluating potential strategic alternatives to maximize shareholder value. As part of the process, the Board is considering a full range of strategic alternatives, which may include financing alternatives, merger, reverse merger, other business combinations, sale of assets, licensing, or other transactions. Calyxt has retained Canaccord Genuity as its financial advisor
- PR Newswire
Calyxt to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, today announced that Michael A. Carr, President and Chief Executive Officer, and Bill Koschak, Chief Financial Officer, will present at the H.C Wainwright 24th Annual Global Investment Conference taking place September 12-14, 2022.
ZacksBears are Losing Control Over Calyxt (CLXT), Here's Why It's a 'Buy' Now
Calyxt (CLXT) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
ZacksCalyxt (CLXT) Reports Q2 Loss, Tops Revenue Estimates
Calyxt (CLXT) delivered earnings and revenue surprises of 6.67% and 36.67%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- PR Newswire
Calyxt Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, today announced financial results for its second quarter ended June 30, 2022.
- PR Newswire
Calyxt to Present at the Canaccord Genuity 42nd Annual Growth Conference
Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, today announced that Michael A. Carr, Chief Executive Officer, and Bill Koschak, Chief Financial Officer, will present at the Canaccord Genuity 42nd Annual Growth Conference taking place August 8-11, 2022.